FX141L

**FX141L** is a somatostatin receptor agonist developed as a therapeutic agent, likely a small molecule analog designed for targeted receptor modulation. It is referenced in the context of hormone receptor agonists alongside established somatostatin analogs like lanreotide and octreotide, suggesting potential applications in conditions involving somatostatin pathway dysregulation, such as neuroendocrine tumors, acromegaly, or other hormone-related disorders. Specific details on its primary indication, clinical development status, or developer are not available in current sources, positioning it as an early-stage or investigational compound.